Business Overview: Haemonetics Corporation (NYSE: HAE)

---

Executive Summary

Haemonetics Corporation is a global healthcare company that provides medical technology for blood and plasma collection, the surgical suite, and hospital transfusion management. It sells into roughly 90 countries through a direct sales force and independent distributors, with customers ranging from biopharmaceutical companies and blood collection organizations to hospitals and group purchasing organizations.

Haemonetics matters because it sits at a genuine chokepoint in the global plasma and blood supply chain and in surgical blood-management workflows — its devices and connected software are embedded in the operational processes of large plasma collectors and hospital systems, not just sold as standalone equipment.

---

1. Core Business Model & How They Work

[ Device Placement (Collection/Surgical Systems) ] ➡️ [ Recurring Disposables & Consumables Revenue ] ➡️ [ Connected Software (NexLynk DMS, Donor360) ] ➡️ [ Embedded Clinical Workflow ]

Haemonetics' economics follow a classic "razor and blades" medical device pattern: placing a capital device (a plasmapheresis machine, an apheresis platelet collector, a hemostasis analyzer) creates a long tail of recurring, high-margin disposables and software revenue, reinforced by the clinical and regulatory switching costs of changing collection or testing protocols once adopted.

---

2. Business Segments

┌─────────────────────────────┐
│    Haemonetics Corporation     │
└───────────────┬───────────────┘
                │
   ┌────────────┼────────────┐
   ▼            ▼            ▼
┌────────┐  ┌─────────────┐ ┌──────────┐
│ Plasma  │  │ Blood Center │ │ Hospital │
│ (43.2%) │  │   (21.1%)    │ │ (34.0%)  │
└────────┘  └─────────────┘ └──────────┘

Plasma (NexSys PCS/PCS2 devices, NexLynk DMS donor management software, the Donor360 app) is the largest and fastest-growing segment. Blood Center (MCS apheresis platelet collection, whole blood collection/storage sets) is explicitly described by the company as operating in "challenging markets" with a deliberate strategy of cost reduction and portfolio narrowing. Hospital splits into Interventional Technologies (VASCADE/VASCADE MVP vascular closure, OptoWire/SavvyWire sensor-guided wires from the OpSens acquisition) and Blood Management Technologies (TEG/HAS hemostasis analyzers, Cell Saver Elite+ cell salvage, SafeTrace Tx/BloodTrack transfusion software).

---

3. Product Portfolio

---

4. Competitive Landscape

• Plasma: Fresenius (Fenwal/Aurora) and Terumo BCT (Rika) are the main device competitors; local Chinese producers such as Nigale and Haier are expanding and represent a longer-term competitive threat in that geography.
• Blood Center: Fresenius, MacoPharma, and Terumo BCT compete largely on quality and price for a shrinking, lower-growth category.
• Vascular closure: Terumo, Abbott, and Cardinal Health.
• Hemostasis testing: Werfen (ROTEM, VerifyNow), Diagnostica Stago (HemoSonics Quantra), and Sysmex — Haemonetics positions itself as the category leader here.
• Cell salvage: LivaNova, Medtronic, and Fresenius.
• Transfusion management software: WellSky, Cerner, and MSoft.

---

5. Strategic Strengths & Risks

Strengths

• Category leadership in viscoelastic testing: a genuinely differentiated clinical niche (TEG) with limited direct substitutes.
• Device + disposables + software bundle: the combination of hardware placement, recurring consumables, and donor-management software creates multiple layers of switching cost at once.
• Diversification across plasma, blood center, and hospital: reduces dependence on any single end market.

Risks

• Customer concentration: the top ten customers are about 48% of net revenue, with CSL alone around 13% — CSL's 2021 notice that it would not renew its exclusive US PCS2 supply agreement (later extended non-exclusively through December 2025) is a direct reminder of this exposure.
• Blood Center secular decline: the segment operates in what the company itself calls "challenging markets," requiring active cost management rather than growth investment.
• Therapeutic substitution risk: new FcRn-targeted and other therapies could reduce demand for plasma-derived products over time, a structural risk to the Plasma segment's addressable market.
• Debt and integration risk: roughly $230 million drawn on the revolver to fund the OpSens and Attune Medical acquisitions, alongside normal integration execution risk.
• Regulatory and IP exposure: FDA, EU MDR/IVDR compliance, and ongoing intellectual property litigation.

---

6. Financial Overview

---

7. Summary Conclusion

Haemonetics' moat is built on embedding its devices, disposables, and software into the daily clinical and operational workflows of plasma collectors and hospitals — switching away from TEG hemostasis testing or NexLynk donor management, once adopted, is operationally painful in a way that a lower-priced competitor's hardware alone cannot easily overcome. The company's biggest strategic tension is balancing active, deliberate decline management in Blood Center against continued investment and share gains in Plasma and Hospital, all while a handful of very large customers like CSL retain real negotiating leverage over the company's largest segment.